Left ventricular hypertrabeculation, an anatomical feature of the heart traditionally linked to higher risk, does not worsen outcomes in patients with dilated cardiomyopathy
The biomarker MR-proADM improves risk prediction in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) and is associated with greater disease severity, mortality, and heart failure events.
The results, published in the European Heart Journal and presented at the European Society of Cardiology Congress, opens the way to new therapies for patients with genetic heart diseases
Scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC), together with cardiologists from Hospital Universitario Puerta de Hierro and the Spanish cardiovascular disease research network (CIBERCV), report that the new discovery makes it possible to identify high-risk patients early and refer them sooner to specialized heart failure units
